Intravenous dexketoprofen vs placebo for migraine attack in the emergency department: A randomized, placebo-controlled trial.

Autor: Gungor F; Antalya Training and Research Hospital, Department of Emergency Medicine, Turkey., Akyol KC; Antalya Training and Research Hospital, Department of Emergency Medicine, Turkey., Kesapli M; Antalya Training and Research Hospital, Department of Emergency Medicine, Turkey., Celik A; Antalya Training and Research Hospital, Department of Emergency Medicine, Turkey., Karaca A; Antalya Training and Research Hospital, Department of Emergency Medicine, Turkey., Bozdemir MN; Antalya Training and Research Hospital, Department of Emergency Medicine, Turkey., Eken C; Akdeniz University Medical Faculty, Department of Emergency Medicine, Turkey cenkereken@akdeniz.edu.tr.
Jazyk: angličtina
Zdroj: Cephalalgia : an international journal of headache [Cephalalgia] 2016 Feb; Vol. 36 (2), pp. 179-84. Date of Electronic Publication: 2015 May 05.
DOI: 10.1177/0333102415584604
Abstrakt: Objective: Migraine is a leading headache etiology that frequently presents to the emergency department (ED). In the present study, we aimed to determine the efficacy of dexketoprofen in aborting migraine headaches in the ED.
Methods: This prospective, randomized, double-blind study was conducted in an ED of a tertiary care hospital using allocation concealment. Patients were allocated into two arms to receive the study drug; 50 mg dexketoprofen in 50 ml saline and 50 ml saline as placebo. Change in pain intensity was measured by the visual analog scale at baseline, both at 30 and 45 minutes after the study medication was administered. Rescue medication requirement and pain relapse were also recorded by a telephone follow-up at 48 hours.
Results: A total of 224 patients (112 in each group) were included into the final analysis. Mean age of the study participants was 37 ± 11 (SD) and 25% (n = 56) of them were male. The median pain improvement at 45 minutes for patients receiving dexketoprofen was 55 (IQR: 49 to 60) and 30 (IQR: 25 to 35) for those receiving placebo. The mean difference between the two groups at 45 minutes was 21.4 (95% CI: 14.4. to 28.5). Rescue drugs were needed in 22.3% of patients who received dexketoprofen compared to 55.4% in patients who received placebo (dif: 33.1%; 95% CI: 20% to 45%). There were no adverse events reported in either group during the study period.
Conclusion: Intravenous dexketoprofen is superior to placebo in relieving migraine headaches in the ED. It may be a suitable therapy with minimum side effects in patients presenting with a migraine headache to the ED.
(© International Headache Society 2015.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje